In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Vibeke Backer discusses how Type 2 inflammation drives severe, uncontrolled CRSwNP. It covers key immune cells and biomarkers (e.g., IL-4, IL-5, IL-13, TSLP), global prevalence differences, and the importance of symptom tracking and targeted therapies.
Join Drs. Victoria Werth and Teri Greiling as they explain the autoimmunity driving bullous pemphigoid (BP), as well as the important role type 2 inflammation plays in BP.

In this video from the 2024 Society for Pediatric Dermatology Symposium held in Toronto, Canada, Dr. Amy Paller, MD explores the possibilities for disease modification in atopic dermatitis.
Dr. Lara Wine Lee discusses the concept of cumulative life course impairment in AD, focusing on non-atopic comorbidities like vertical growth deficits and mental health impairment and how these might be preventable with early intervention at PeDRA 2025.
Prof Jean-David Bouaziz describes the multifaceted burden of atopic dermatitis, beyond what can be seen on the skin, at EADV 2025.
This is the ADVENT-branded video of the IDEF presentation that was presented during the 1-hour webinar on December 1st featuring both Dr. Sarina Elmariah and Dr. Jason Hawkes.

This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
This is the full presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida, presenting the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
Professors Bouaziz and Paller discuss the clinical burden and potential biomarkers of subclinical control in AD, at EADV 2025.
Dr. Yu and Dr. Wine Lee discuss the clinical presentation and burden of atopic dermatitis, the role of type 2 inflammation in the development of atopic comorbidities, and the importance of early intervention in potentially preventing cumulative life course impairment in AD at PeDRA 2025.
Dr. Jeff Yu presents the clinical presentation of pediatric AD and highlights how type 2 inflammation contributes to symptoms and development of atopic comorbidities such as food allergy and asthma at PeDRA 2025